CUPERTINO, Calif, May 2 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today
that Peter J. Langecker, M.D., Ph.D. has joined the Company as Chief Medical
Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)
“DURECT is committed to diligently moving its products through the
clinical development stages. Further to that objective, we are very fortunate
to have Dr. Langecker join us with his expertise in clinical trial design,
execution, and analysis as our pipeline progresses into later stages of
development and as we focus on development of products for which we will
retain commercialization rights,” said James E. Brown, DVM, President and CEO
of DURECT.
Dr. Langecker joins us from Intarcia Therapeutics, Inc. where he served as
Chief Medical Officer and Vice President Clinical Affairs. He received his
doctorate in medical sciences from the Ludwig-Maximilians University in
Munich. He trained in hematology and oncology and has extensive experience in
developing drugs and biological products in both Europe and the United States.
Dr. Langecker was formerly based in Switzerland where he developed a variety
of products for Novartis. He came to the U.S. as a Director in Clinical
Research for Schering-Plough and as Vice President, Clinical Research for
Coulter Pharmaceuticals. More recently he served as Vice President of Clinical
Affairs for SUGEN, Inc. until its merger with Pharmacia & Upjohn. Dr.
Langecker has also served as a Director for Xcyte Therapies based in Seattle,
WA.
About DURECT Corporation
DURECT Corporation is an emerging specialty pharmaceutical company focused
on the development of pharmaceutical systems based on its proprietary drug
delivery platform technologies that treat chronic debilitating diseases and
enable biotechnology products. Additional information about DURECT is
available at www.www.durect.com.
DURECT Forward-Looking Statement
The statements in this press release regarding DURECT’s products in
development and future clinical trial plans are forward-looking statements
involving risks and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, DURECT’s ability to
successfully design, enroll, conduct and complete clinical trials, complete
the design, development, and manufacturing process development of the product
candidate, obtain product and manufacturing approvals from regulatory agencies
and manufacture and commercialize the product candidate, as well as
marketplace acceptance of the product candidate. Further information regarding
these and other risks is included in DURECT’s Annual Report on Form 10-K filed
with the SEC on March 16, 2006 under the heading “Risk Factors.”
SOURCE:
DURECT Corporation
05/02/2006
CONTACT:
Schond L. Greenway, Vice President, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417/
Web site: http://www.www.durect.com
(DRRX)